To assess whether Australia’s August 2023 removal of prescribing and dispensing restrictions was followed by increased pharmacy ordering of mifepristone-misoprostol and broader geographic distribution of pharmacies ordering it.
Approach:
Design: Interrupted time-series analysis of monthly sales to community and hospital outpatient pharmacies.
Data and period: Sales records from Australia’s sole distributor during the study period, covering 24 months before the change (August 2021–July 2023) and 24 months after it (August 2023–July 2025).
Interpretation:
The provided context describes the study rationale, regulatory change, and methods but does not report study results.
Limitations:
The supplied article context ends before the study results and does not provide findings on pharmacy ordering or geographic distribution.
The analysis used sales records from the sole distributor during the study period.
Conclusion:
On August 1, 2023, the TGA removed prescribing and dispensing restrictions on mifepristone-misoprostol in Australia. The supplied article context does not report the study’s results on pharmacy ordering or geographic distribution.
